IL18 and metabolic dysfunction-associated steatohepatitis: In comparison to non-NASH patients, NASH patients exhibit significantly higher levels of NLRP3, caspase-1, proIL-1β, and pro-IL-18 in liver samples, and their expression is associated with the development/severity of fibrosis (Shi et al., 2023).